HAEMONETICS CORP — Director's Dealing 2022

Sep 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2022-09-15

Reporting Person: Basil Michelle L (EVP and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-15	Common Stock	M	11154	$38.43	Acquired	51789	Direct
2022-09-15	Common Stock	M	14231	$41.64	Acquired	66020	Direct
2022-09-15	Common Stock	M	3173	$56.57	Acquired	69193	Direct
2022-09-15	Common Stock	S	27769	$77.76	Disposed	41424	Direct
2022-09-15	Common Stock	S	6029	$78.50	Disposed	35395	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-15	Non-qualified Stock Option (Right to Buy)	$38.43	M	11154	Disposed	2024-03-06	Common Stock (11154)	Direct
2022-09-15	Non-qualified Stock Option (Right to Buy)	$41.64	M	14231	Disposed	2024-06-06	Common Stock (14231)	Direct
2022-09-15	Non-qualified Stock Option (Right to Buy)	$56.57	M	3173	Disposed	2028-05-18	Common Stock (3173)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive.

F5: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.